The Current Vitiligo Treatment Landscape, From Topicals to Orals

"The Current Vitiligo Treatment Landscape, From Topicals to Orals" takes up the question of where each modality — topicals, phototherapy, orals, and procedures — fits into the current vitiligo treatment landscape.

Dr. Rosmarin walks through the full range of vitiligo treatment modalities: topical, oral, systemic, and procedural. Topical corticosteroids and calcineurin inhibitors remain foundational, with calcineurin inhibitors preferred for sensitive areas like the head, neck, and genitals. Ruxolitinib cream, approved in 2022 as the first and still only FDA-approved vitiligo treatment, has expanded options considerably; he uses it first-line in some patients and in combination with corticosteroids or calcineurin inhibitors in others, depending on payer requirements or clinical scenario. He still considers tacrolimus ointment reasonable as first-line therapy in select cases.

Phototherapy, particularly narrowband UVB, remains an important complementary modality because vitiligo treatment requires two simultaneous actions: calming the immune system and stimulating pigment cells. Phototherapy addresses the latter, making combination approaches synergistic. Its main limitations are access and convenience, since many dermatology practices lack phototherapy equipment and many trainees never learn to use it well. High copays and inconvenient office visits push some patients toward home phototherapy, though payers often require documented success with in-office treatment first, and some patients purchase their own devices online.

Oral supplements like polypodium and ginkgo biloba see occasional use, typically alongside phototherapy. Off-label oral JAK inhibitors are already in use by many clinicians, with Phase 3 data emerging and approval of roughly three agents expected within the next year. Procedures such as melanocyte transfer, which relocates pigment-producing cells to affected areas, are almost never covered by insurance. Dr. Rosmarin emphasizes that because repigmentation is so difficult, most patients ultimately require combination therapy delivered concurrently rather than in strict sequence.

The next episode in this series, "How JAK Inhibitors Are Reshaping Vitiligo Treatment Goals," features Dr. Desai and Dr. Lal examining how JAK inhibitors are reshaping treatment goals.